Rationale: To maintain vascular patency, endothelial cells (ECs) actively regulate hemostasis. Among the myriad of pathways by which they control both fibrin formation and fibrinolysis is EC expression of annexin A2 (ANXA2) in a heterotetrameric complex with S100A10 [(ANXA2-S100A10)2]. This complex is a well-recognized endothelial surface platform for the activation of plasminogen by tissue plasminogen activator. A noteworthy advance in this field came about when it was shown that the cAMP pathway is linked to the regulation of (ANXA2-S100A10)2 in ECs. Objective: These findings prompted us to determine whether a druggable target, namely the exchange protein directly activated by cAMP (EPAC) pathway, plays a role in vascular luminal fibrinolysis. Methods and Results: Taking advantage of our Epac1-null mouse model, we found that depletion of Epac1 results in fibrin deposition, fibrinolytic dysfunction, and decreased endothelial surface ANXA2 in mice, which are similar to phenomena discovered in ANXA2-null and S100A10-null mice. We observed upregulation of EPAC1 and downregulation of fibrin in endocardial tissues beneath atrial mural thrombi in humans. Of note, our thrombosis model revealed that dysfunction of fibrinolysis in EPAC1-null mice can be ameliorated by recombinant ANXA2. Furthermore, we demonstrated that suppression of EPAC1 using a small-molecule inhibitor (ESI09) reduces the expression of ANXA2 in lipid rafts and impedes ANXA2 association with S100A10. Endothelial apical surface expression of both ANXA2 and S100A10 were markedly decreased in ESI09-treated ECs, which was corroborated by results from a nanoforce spectroscopy study. Moreover, inactivation of EPAC1 decreases tyrosine 23 phosphorylation of ANXA2 in the cell membrane compartment. Conclusions: Our data reveal a novel role for EPAC1 in vascular fibrinolysis, by showing that EPAC1 is responsible for the translocation of ANXA2 to the EC surface. This process promotes conversion of plasminogen to plasmin, thereby enhancing local fibrinolytic activity.
Introduction
. Recent reports showed that, in primary human ECs, (ANXA2-S100A10)2 is involved in the forskolin-induced cAMP-dependent secretion of vWF 25 . Moreover, the Epac-Rap1 pathway can regulate exocytosis of the exocytotic organelles called Weibel-Palade bodies, in which vWF is stored 55 . These findings prompted us to determine whether the cAMP-EPAC signaling axis plays a role in balancing blood coagulation and fibrinolysis on the vascular interior wall surface. In the present study, by taking advantage of EPAC1-null mice and an EPAC-specific inhibitor, we show that EPAC1 plays a novel important role in maintaining vascular patency. Using biochemical and biomechanical assays, we found that EPAC1 exerts its regulation on vascular fibrinolysis via modulating endothelial surface expression of ANXA2 and its association with S100A10.
Materials and Methods Patients and samples
In four cases of rheumatic mitral stenosis with chronic atrial fibrillation, left atrial mural thrombi were seen in the left atrial appendages during open heart surgeries for mitral valve replacements under extracorporeal circulation support at Changhai Hospital, the Second Military Medical University (Shanghai, China). After removing the thrombus, a 5 x 5 mm 2 piece of endocardial tissue directly underneath the thrombus in the left atrial appendage was harvested. Tissue samples were flash frozen in liquid nitrogen and homogenized for immunoblotting assays by pulverizer (Spectrum Laboratories, Rancho Dominiquez, CA) as described previously 56 . The biopsy incision was closed with a 5-0 polypropylene suture. Similar tissue samples from normal donor hearts were used as normal controls. Informed written consent was obtained from each patient prior to study enrollment. This study was approved by the Committee on Ethics of Changhai Hospital.
Atomic force microscopy (AFM)
The biomechanical properties of ANXA2 and S100A10 at the cell surface were studied using an AFM system (Flex-AFM, Nanosurf AG, Liestal, Switzerland) that utilized relevant antibody-functionalized AFM probes. Colloidal cantilevers with a 5 µm polystyrene bead were used (SHOCON-G-PS, Applied NanoStructures, Mountain View, CA) to measure surface protein interaction forces 57, 58 . The cantilevers were functionalized by incubation with anti-ANXA2 mAb or anti-S100A10 mAb at 100 g/L in 0.1 mol/L NaHCO3 (pH 8.6) overnight at 4°C. Unbound proteins were rinsed off using PBS. The exposed surface of the bead was blocked by BSA (Sigma, St. Louis, MO) at 500 g/L in PBS 58 . AFM imaging and measurements were generally taken within 1 h after blocking. The spring constant of the cantilever was calibrated using the Sader method in air 59 . The cantilever spring constant varied between 0.10-0.15 N/m. Force spectroscopy was done in static force mode operating on 25 µm 2 areas on a living cell surface. The functionalized cantilever was manipulated into contact with the surface of a confluent monolayer of HUVECs. The maximum compression force was set to 150 pN. The contact time was kept constantly at 500 ms before the cantilever was retracted at a constant pulling speed of 1 µm/s to measure the forceextension curve. In order to evaluate the effect of nonspecific unbinding force, confluent cell monolayers were pretreated with ANXA2 or S100A10 antibodies at 25 g/L for 30 min to block ANXA2 or S100A10 on the cell surface before the AFM measurements. We scanned five cells per group, each with a different cantilever. Force-distance curves were analyzed using the open source software Atomic J 60 .
Statistics
Statistical significance was determined using Student's t test. Results were regarded as significant if 2tailed P values were < 0.05. All data are expressed as mean ± standard error of the mean. Results
Absence of the EPAC1 gene results in fibrin accumulation in the microvasculature
To ascertain the role of EPAC1 in vivo, we generated EPAC1-null mice that carry the Rapgef3 (also known as EPAC1) allele lacking exons 3-6. We confirmed that the mutant allele is null by Western immunoblotting analysis (WB) ( Fig. S1 ). Similar to published models 61, 62 , our EPAC1-null mice are viable, fertile, and without overt abnormalities.
In vitro evidences suggested EPAC1 controls vascular endothelial (VE)-cadherin-mediated cell junction formation [39] [40] [41] . Given an in vivo study showing that deletion of EPAC1 inhibits endothelial barrier baseline in skin and intestine, but not heart 61 , we assessed vascular integrity in brain and lung in our EPAC1-null model. Compared to wild-type mice, the Evans blue assay revealed no differences in the baseline of extravascular dye in brain and lung parenchyma in EPAC1-null mice; immunofluorescent microscopy (IF) analysis displayed similar structures of vascular tight or adherens junctions ( Fig. S2) .
Excessive accumulation of intra-and extravascular fibrin is a hallmark of enhanced blood coagulation or incomplete fibrinolytic function caused by plasminogen or plasminogen activator deficiency in mice 8, 14 . We employed immunohistochemistry (IHC) to measure fibrin levels in EPAC1-null and wild-type mice. Increased fibrin signals were detected within brain, lung, and renal blood vessels in EPAC1-null mice, while comparable staining was not detected in similar tissues from wild-type mice ( Fig. 1 and Fig. S3) . WB displayed increased level of fibrin within tissues of lung and kidney in EPAC1-null mice, compared to wild-type mice ( Fig. 1) . Interestingly, IHC studies on tissues from wild-type mice treated with a small molecule EPAC-specific inhibitor, ESI09 (10 mg/kg/day, given intraperitoneally for 5 days) 63 , recapitulated IHC findings in the EPAC1-null mice. Increased fibrin immunostaining within tissues of multiple organs was evident ( Fig. 1) . A similar phenomenon was not observed in wild-type mice treated with vehicle only. These data suggest that EPAC1 deficiency causes fibrin accumulation in a subset of tissues. We next examined blood coagulation function in EPAC1-null mice to determine whether fibrin accumulation is caused by enhanced blood coagulation. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are two biochemical indicators of blood coagulation 8 . We observed that there were similar values of PT and aPTT between wild-type and EPAC1-null mice ( Fig. S4 ), suggesting that EPAC1 depletion does not affect the blood coagulation pathway characterized by these two assays. We also examined the platelet count and the platelet reactivity by measuring bleeding time 64 . We observed no differences between wild-type and EPAC1-null mice ( Fig. S4) .
Taken together, excessive accumulation of fibrin in the vasculatures in EPAC1-deficient mice is likely caused by impaired fibrinolytic activity rather than enhanced blood coagulation. Therefore, EPAC1 may play a regulatory role in baseline fibrinolytic homeostasis.
Reduced expression of EPAC1 in endocardial tissues underneath atrial mural thrombi in humans
Hypofibrinolysis was documented in rheumatic or non-rheumatic chronic atrial fibrillation patients, and associated with high thromboembolic risk 65, 66 . We collected endocardial tissues (including cardiac endothelium) underneath surgery-confirmed left atrial mural thrombi from four cases of rheumatic mitral stenosis with chronic atrial fibrillation. The heart endocardium is primarily made up of cardiac ECs, which are derived from vascular ECs 67 . Interestingly, WB analysis displayed that EPAC1 expression was prominently decreased, with increased levels of fibrin in the endocardial areas underneath the atrial mural thrombi compared to control tissue from normal donor hearts ( Fig. 2) . IF analysis displayed, compared to control tissue, enhanced fibrin deposition colocalized with reduced signal of EPAC1 in the endocardium and intima layer of coronary blood vessels in the cardiac wall ( Fig. 2) . This suggests that there is a correlation between reduced EPAC1 and deposition of fibrin in endothelium during formation of mural thrombi in human hearts.
Deletion of EPAC1 makes mouse susceptible to chemical-induced carotid arterial occlusion
The ferric chloride (FeCl3)-induced rodent carotid artery thrombosis model is a well-established experimental model for studying vascular fibrinolytic activity in vivo. In the model, the arterial occlusion caused by thrombus formation is measured by monitoring blood flow with a Doppler probe 14, [68] [69] [70] . Using this model, we examined vascular fibrinolytic function in wild-type and EPAC1-null mice by comparing the maximal arterial occlusion (as % of baseline blood flow rate) (MaxO), maximal recovery of blood flow over 30 minutes after exposure to FeCl3 (as % of baseline blood flow rate) (MaxR) 14 , and histological observation of FeCl3-induced carotid arterial thrombosis. Typical patterns of blood flow curves recorded during these experiments are illustrated ( Fig. 3) . Baseline blood flow was measured first, and there was no statistical difference between wild-type and EPAC1-null mice (1.9556 ± 0.1078 mL/min vs. 1.7694 ± 0.1265 mL/min, p=0.2748). Acute arterial thrombosis was induced by application of 7.5% FeCl3 to the adventitial arterial surface of the carotid artery 14 . Compared to wild-type mice, EPAC1-null mice demonstrated a significantly higher MaxO (36.40 ± 4.32 vs. 73.55 ± 7.95, P < 0.01) and a lower MaxR (80.44 ± 4.97 vs. 31.49 ± 9.01, P < 0.01) for FeCl3-exposed carotid arteries. Furthermore, in a blinded study of hematoxylin and eosin (H&E)-stained cervical tissue, thrombi were detected in 8.33% of wild-type mice; in EPAC1-null mice, the incidence of detected thrombi was 0.42 (Table) (Fig. S5) . These results indicate that EPAC1-null mice suffer more severe acute arterial occlusion caused by FeCl3induced thrombosis. The observation that EPAC1-null mice are susceptible to chemical-induced carotid arterial thrombosis, coupled with evidence that decreased expression of EPAC1 in human cardiac endothelia is associated with fibrin deposition on the surface, suggests that EPAC1 plays a role in regulation of vascular accumulation of fibrin.
Reintroduction of ANXA2 attenuates chemical-induced vascular occlusion in EPAC1-null mice
We next sought to delineate the cellular and molecular mechanisms by which EPAC1 might be involved in regulation of vascular accumulation of fibrin. EPAC1 is an intracellular sensor of cAMP. In our study, EPAC1-null mice showed an impaired ability to resist FeCl3-induced thrombosis, which is similar to the phenotypes observed in ANXA2-null mice 14 and S100A10-null mice 8 . ANXA2 and S100A10 form a complex that is the most studied tPA binding receptor expressed abundantly in ECs 7, 9, [11] [12] [13] . Furthermore, recombinant ANXA2 (rANXA2) can reduce thrombus formation in the FeCl3-induced rodent carotid artery thrombosis model 68 . We introduced rANXA2 intravenously (i.v.) 68 into EPAC1-null mice to evaluate whether vascular occlusion can be restored.
Treatment with rANXA2 or bovine serum albumin (BSA) induced no changes in baseline blood flow in either wild-type or EPAC1-null mice ( Fig. 3) . After exposure to FeCl3, there was no significant difference in either MaxO or MaxR between wild-type and EPAC1-null mice when they were both pretreated with rANXA2 ( Fig. 3) . EPAC1-null mice pretreated with BSA showed decreased MaxO and increased MaxR of the FeCl3-exposed carotid artery, compared to the EPAC1-null mice pretreated with rANXA2. Blinded histological examination revealed that thrombi were detected in 40% of EPAC1-null mice pretreated with BSA; in EPAC1-null mice pretreated with rANXA2, the incidence of detected thrombi was 9.09% (Table) . Moreover, we isolated biotinylated mouse aortic endothelial surface proteins from mice and revealed decreased cell surface ANXA2 in EPAC1-null mice (Fig. 3) . These data indicate that attenuated blood flow resulting from EPAC1 depletion correlates with impaired ANXA2-mediated endothelial surface fibrinolytic activity and can be restored by i.v. administration of rANXA2. We also assessed the soluble part of the fibrinolytic system by measuring euglobulin clot lysis time 71 and found no differences between wild-type and EPAC1-null mice (Fig. S4) . These observations suggest that the fluid-phase soluble fibrinolytic system was intact in EPAC1-null mice, a finding that is consistent with reduced extracellular ANXA2.
Inhibition of EPAC1 affects the interaction of ANXA2 with lipid rafts and impedes ANXA2 association with S100A10 in ECs
Given the fact that elevated levels of intra-endothelial cAMP can stabilize (ANXA2-S100A10)2 25 , we examined the correlation among EPAC1 expression and the levels and association of ANXA2 and S100A10. First, we performed qRT-PCR and immunoblotting to measure mRNA and protein levels of ANXA2 and S100A10 in tissues from wild-type and EPAC1-null mice. There was no significant difference in either mRNA or protein levels between wild-type and EPAC1-null mice in brain, lung, and kidney tissue ( Fig. S6) , suggesting that depletion of EPAC1 does not affect de novo protein synthesis of ANXA2 and S100A10 in these tissues.
Taking advantage of the EPAC-specific inhibitor ESI09, we determined the effect of EPAC1 inhibition on endothelial expression of ANXA2 and its partner S100A10 in the cellular membrane compartment. We treated HUVECs with ESI09 to inhibit EPAC1. Similar levels of mRNA and ANXA2 and S100A10 proteins were detected in vehicle-and ESI09-treated cells (Fig. S6) , indicating no correlation between pharmacological inactivation of EPAC1 and de novo protein synthesis of ANXA2 and S100A10. However, immunoprecipitation assays with EC samples demonstrated that ESI09 treatment reduced associated ANXA2 in S100A10 precipitates, suggesting decreased formation of (ANXA2-S100A10)2 in ECs (Fig. 4A) .
It has been established that ANXA2 binds to negatively charged phospholipids in cellular membranes. We therefore employed ultracentrifugation to isolate lipid rafts from membrane fraction samples of HUVECs in detergent conditions 72 . We obtained highly purified lipid rafts (Fig. S7) . In the vehicletreated group, ANXA2 is still associated with lipid rafts after sample processing by ultracentrifugation. WB analysis revealed a significantly lower level of ANXA2 in lipid rafts in the ESI09-treated group compared to the vehicle-treated group (Fig. 4B) .
These data suggest that inactivation of EPAC1 interrupts ANXA2 binding to the cell membrane and its association with S100A10. 6. Inhibition of EPAC1 decreases ANXA2 and S100A10 residing on EC apical surfaces Both ANXA2 and S100A10 reside on the luminal surface of ECs mainly in the form of (ANXA2-S100A10)2, a functional unit for plasmin-mediated fibrinolysis. To examine whether EPAC1 regulates the appearance of this crucial determinant for fibrinolytic activity on the EC luminal surface, we probed the expression levels of ANXA2 and S100A10 on the EC apical surface using biochemical and biomechanical approaches. We performed impermeable cell-based ELISA assays 73, 74 to probe the cell surface levels of ANXA2 and S100A10. Endothelial surface levels of ANXA2 and S100A10 were determined as relative fluorescence units corrected for cell protein (FU/A550). Comparing vehicle-and ESI09-treated HUVECs in 96-well plates demonstrated that EPAC inhibition significantly decreased ANXA2-(P < 0.05) and S100A10-specific (P < 0.05) signals on the surfaces of HUVECs (Fig. 5A) .
To further validate these results, we used atomic force microscopy (AFM) to quantify the distribution of ANXA2 and S100A10 on the surface of ECs. AFM is an advanced tool for studying biomechanical properties and has been used to determine the expression levels of cell surface proteins by measuring the binding affinity of specific protein-protein interactions, including antigen-antibody and receptor-ligand, with nanoforce spectroscopy 58, 75 . In our study, anti-ANXA2 or S100A10 antibodies were immobilized on polystyrene spheres attached to a colloidal cantilever. We measured the specific unbinding force during rupture of the interaction between the antigen (ANXA2 or S100A10) expressed at the apical surface of living HUVECs and the antibody-coated AFM cantilever probe. Interactions between antibodies on the AFM cantilever and cell surface antigens cause large adhesion forces, which are quantified by the deflection signal during separation of the cantilever from the cell. By tracking the cantilever deflection and retraction cycle, the binding, stretching, and ruptures of antibody-antigen complexes can be monitored in terms of the adhesive force changes on the cantilever over the distance traveled by the cantilever. Representative force-distance (FD) curves exhibit rupture events occurring during the interaction between antigens and antibodies in designated fields on the surface of a single living HUVEC (Fig. 5B) . Therefore, by integrating the areas underneath the FD curve and above the baseline (zero force in Fig. 5B) , we calculated the work that is required to break all interactive bonds between the cantilever and the EC, reflecting the quantity of antigen expression on the surface 58, 75 . Using an ANXA2 antibody-coated cantilever, greater unbinding work was measured on the surface of HUVECs exposed to vehicle compared with that of HUVECs exposed to ESI09 (3.568 ± 0.132 x 10 4 pN*nm vs. 1.956 ± 0.072 x 10 4 pN*nm, P < 0.01), indicating that more ANXA2 antigens were detected on the surface of vehicle-treated HUVECs than ESI09-treated HUVECs (Fig. 5C ). This suggests that EPAC1 inhibition reduces the amount of ANXA2 residing at the cell surface. Similarly, results obtained from using S100A10 antibody-coated cantilevers showed greater unbinding force on the surface of HUVECs exposed to vehicle compared to HUVECs exposed to ESI09 (3.075 ± 0.091 x 10 4 pN*nm vs 1.119 ± 0.051 x 10 4 pN*nm, P < 0.01), suggesting more S100A10 antigens were detected on HUVEC surfaces of the vehicletreated group than the ESI09-treated group (Fig. 5C) . The presence of the blocking antibody resulted in a significant decrease in the adhesion interaction between normal cells and the functionalized cantilever. These nano-biomechanical data corroborated the evidence gained from our biochemical studies that demonstrated that EPAC1 regulates the expression of ANXA2 and S100A10 on EC apical surfaces.
Inhibition of EPAC1 decreases tyrosine 23 phosphorylation of ANXA2 (Y23phANXA2) in the cell membrane compartment
ANXA2 binding to and translocation across the cell membrane are believed to be regulated via posttranslational modification of ANXA2, mainly phosphorylation or dephosphorylation of the Nterminal domain 25, 76 . Phosphorylation of tyrosine 23 (Y23) influences ANXA2 binding to lipid rafts 23 . We examined Y23phANXA2 in HUVECs exposed to vehicle and ESI09. We observed that ESI09 decreased Y23phANXA2 in the membrane fractionation ( Fig. 6) , suggesting that EPAC1 regulates the dynamics of ANXA2, possibly by modulating phosphorylation or dephosphorylation of the N-terminal domain of ANXA2.
Discussion Interrupted blood flow caused by a thrombus is the pathological foundation of some major human diseases. Fibrin, which is the main structural scaffold of a blood clot, is the ultimate product of coagulation and the major target of fibrinolysis 77 . Excessive accumulation of fibrin in tissue can be caused by enhanced blood coagulation or insufficiency in fibrinolytic function 8 . We detected increased fibrin accumulation in the microvasculature of multiple organs in EPAC1-null mice compared with wild-type mice, while there were no differences in measurements of PT and PTT assays, platelet count, and bleeding time. Reintroduction of ANXA2 attenuates chemical-induced vascular occlusion in EPAC1-null mice. This observation suggests that the increased fibrin accumulation detected in EPAC1-null mice is likely the result of impaired fibrinolysis rather than enhanced blood coagulation.
Plasmin, generated by cleavage of zymogen plasminogen, is the key protease involved in the dissolution of a fibrin clot. Among identified endothelial surface plasminogen and PA binding receptors, the (ANXA2-S100A10)2 has been potentially linked to the cAMP-EPAC signaling axis. In the context of coagulation-relevant regulation in HUVECs, the formation and stabilization of (ANXA2-S100A10)2 occurs in a cAMP-dependent manner 25 . The cAMP-EPAC pathway has been studied in cellular biological activities such as cell adhesion, cell junction, cell secretion, and cell differentiation 32, 38 . In ECs, EPAC1 and not EPAC2 is the dominant functional isoform 1, 43, 53 . EPAC1 is responsible for endothelial microtubule dynamics, cell secretion, angiogenesis, and barrier functions 1, 25, 40, 47 . In the present study, our EPAC1-null mice displayed excessive fibrin accumulation in the microvasculature of multiple organs. Compared with wild-type mice, EPAC1-null mice showed an inability to resist acute arterial occlusion caused by FeCl3-induced thrombosis. These results suggest that EPAC1 deficiency impaired fibrinolytic function. Our study, for the first time, showed the possible role of EPAC1 in regulating ECs fibrinolysis.
Interestingly, ANXA2-null mice 14 and S100A10-null mice 8 both also exhibited impaired fibrinolytic function, strongly suggesting that EPAC1 and (ANXA2-S100A10)2 may act cooperatively to mediate the fibrinolytic pathway. Employing biochemical and biomechanical technologies, we have obtained the following new lines of evidence: (1) inactivation of EPAC1 hampered the association between ANXA2 and S100A10 in ECs; (2) inactivation of EPAC1 decreased ANXA2 and S100A10 expression in ECs at the apical surface; and (3) AFM experiments revealed a dramatic reduction in the interactive forces between ANXA2-or S100A10-functionalized cantilevers and endothelial surfaces after inhibition of EPAC1 in ECs.
Taken together, these data reveal a tight association between EPAC1 and the dynamics of (ANXA2-S100A10)2 in ECs. (ANXA2-S100A10)2, which is expressed on both resting and activated ECs, possesses binding affinity for both plasminogen and tPA and serves as receptor for tPA-dependent plasmin generation on endothelial luminal surfaces 9, [11] [12] [13] . Regulation of this heterotetramer, either by formation, stabilization, or translocation, modulates fibrinolytic activity on the EC luminal surface. The fact that EPAC1-null mice given rANXA2 intravenously gained the capability to attenuate acute arterial occlusion in chemical-induced thrombosis model further supports our interpretation that EPAC1 plays a critical role in (ANXA2-S100A10)2-mediated vascular fibrinolysis.
Despite our evidence supporting a connection between EPAC1 and (ANXA2-S100A10)2-mediated fibrinolysis, the underlying mechanism remains unclear. Translocation of (ANXA2-S100A10)2 occurs independently of the classical endoplasmic reticulum-Golgi pathway and does not involve de novo protein synthesis 11, 22, 78 . The S100A10-binding motif is found in the N-terminal domain of ANXA2 12, 79 . ANXA2 lacks a typical signal peptide 22 . ANXA2 in the cellular membrane compartment is believed to be regulated mainly via phosphorylation/dephosphorylation of the N-terminal domain of ANXA2 25, 76 , which is catalyzed by Ser/Thr kinases, Ser/Thr phosphatase, or Tyr kinase 22, 25, 76 . Brandherm et al. 25 identified that serine 11 dephosphorylation in ANXA2, catalyzed by a calcineurin-like phosphatase, is a positive switch for cAMP-dependent extracellular trafficking of (ANXA2-S100A10)2. Furthermore, He et al. reported that protein kinase C-activated phosphorylation of ANXA2 at serine 11 and 25 resulted in disassociation of the (ANXA2-S100A10)2 and prevented ANXA2's translocation to the cell surface 76 . Y23phANXA2 was identified as another regulatory switch during association of ANXA2 with lipid rafts 23 and translocation of (ANXA2-S100A10)2 22 . After Y23phANXA2 through a Src-like tyrosine kinase-dependent pathway, the heterotetramer is translocated to the cell surface by an as yet unknown mechanism 22 . In this study we have shown that inactivation of EPAC1 by ESI09 decreased Y23phANXA2 in the EC membrane compartment, suggesting that EPAC1 may regulate ANXA2 phosphorylation/dephosphorylation and thus play a pivotal role in the dynamics of (ANXA2-S100A10)2. We are currently investigating the mechanism and pathway underlying this correlation.
In conclusion, our studies combined an in vitro primary human endothelial system with an in vivo model and linked EPAC1 with the (ANXA2-S100A10)2-based fibrinolytic pathway to reveal a novel role for EPAC1 in vascular fibrinolysis. In ECs, EPAC1 is responsible for the formation and translocation of (ANXA2-S100A10)2, a key endothelial surface platform for tPA and plasminogen, aiding the conversion of plasminogen to plasmin. Wild-type (n=4) and EPAC1-null mice (n=11) were treated with rANXA2, showing no difference in MaxO and MaxR. Compared to EPAC1-null mice pretreated with BSA (n=5), EPAC1-null mice pretreated with rANXA2 show lower MaxO (*P < 0.01) and higher MaxR (*P < 0.01) (C). Western immunoblotting analysis showed reduced cell surface expression of ANXA2 in vivo (D).
Fig. 4: Inhibition of EPAC1 interrupts ANXA2 binding to lipid rafts and ANXA2 association with S100A10 in HUVECs.
Western immunoblotting shows decreased levels of associated ANXA2 in S100A10 precipitates in ESI09-treated HUVECs, compared with vehicle-treated HUVECs (A) (*P < 0.05). ANXA2 levels were presented as percentages of the indicated loading controls in densitometry. Significantly reduced ANXA2 was detected in lipid rafts from ESI09-treated HUVECs, compared with vehicle-treated group (B) (*P < 0.01). A cell lysate was used as positive control. ANXA2 levels were presented as percentages of the positive controls in densitometry. Equal loading amounts of proteins were confirmed with lipid raft-and non-lipid raft-specific assays (Fig. S7) . All experiments were repeated three times.
Fig. 5: Inhibition of EPAC1 impedes ANXA2 and S100A10 residing on endothelial apical surfaces.
An impermeable cell-based ELISA assay was employed to compare ANXA2 and S100A10 in ESI09-and vehicle-only treated HUVECs (A). Compared with the vehicle-treated group, ESI09-treated HUVECs show lower relative fluorescence units corrected for cell protein (FU/A550) of ANXA2 and S100A10 (* P < 0.05) signals on the surfaces of HUVECs. The data presented are representative of three independent experiments. The unbinding work of cell surface antigens with a relevant antibody on a cantilever surface was quantified by force-distance curve-based atomic force microscopy (AFM) (representative curves in B). During static force mode spectroscopy as the cantilever is pulled up from the cell surface, the unbinding force reaches its peak before all antigen-antibody interactions rupture. These specific unbinding force measurements can be compiled for quantification of total ANXA2 or S100A10 expression on selected areas on the HUVEC cell surface (C). With ANXA2 or S100A10 antibody-coated cantilevers, the unbinding work of vehicle-treated HUVECs is higher than that of ESI09-treated HUVECs (*P < 0.01), indicating reduced cell surface ANXA2 and S100A10 expression after ESI09 treatment. Ab block: ANXA2 antibody and S100D10 antibody at 25 g/mL for 30 min in medium, respectively, before the AFM measurement. Densitometry was used to quantify the relative intensity of tyrosine23-phosphorylated ANXA2-specific immunoblots normalized by the indicated loading controls (B). All experiments were repeated three times. Fig. S1 . Generation of EPAC1-null mice. Fig. S2 . Vascular integrity assessments. Fig. S3 . Normal mouse IgG was used as an antibody control during immunohistochemistry. Fig. S4 . Comparison of clotting parameters. Fig. S5 . Histological observation of FeCl3-induced carotid arterial thrombosis. Fig. S6 . Absence or inhibition of EPAC1 does not affect de novo protein synthesis of ANXA2 and S100A10. Fig. S7 . Lipid raft fraction-associated monosialotetrahexosyl ganglioside assay and non-lipid raft fractionassociated immunoblotting with anti-transferrin receptor.
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